news Novel targeting peptide shows promise against COVID-19 cytokine storm 3 July 2020 | By Hannah Balfour (Drug Target Review) Experimental peptide combination TAT CARMIL1 reduced collagen degradation as a result of cytokine storm in ex vivo study.
news Study reveals how SARS-CoV-2 rewires human proteins for replication 1 July 2020 | By Victoria Rees (Drug Target Review) A team of researchers has analysed how SARS-CoV-2 hijacks the proteins in its host cells to aid replication and infect nearby cells.
news Therapies targeting AhRs and IDO1 could combat COVID-19, paper says 30 June 2020 | By Victoria Rees (Drug Target Review) Researchers have hypothesised that treatments targeting the downregulation of AhRs and IDO1 genes could reduce severity of COVID-19 infection.
news Promising COVID-19 drug candidate identified by virtual screening 25 June 2020 | By Victoria Rees (Drug Target Review) After virtually screening 640 existing drug compounds, researchers have revealed that PC786 potently targets several SARS-CoV-2 receptors, making it a candidate to fight COVID-19.
news Over 718 drugs in pipeline as potential COVID-19 treatments, says report 25 June 2020 | By Victoria Rees (Drug Target Review) New research has found that of the 718 pipeline drugs associated with COVID-19, 70 percent are currently in the discovery or pre-clinical stages.
news PL8177 shows success as COVID-19 therapy in pre-clinical trials 24 June 2020 | By Victoria Rees (Drug Target Review) The drug candidate PL8177 reduced inflammation, protected lung tissue and reduced lung fibrosis in pre-clinical models with symptoms of COVID-19.
news N terminal domain of S protein revealed as antibody target for COVID-19 23 June 2020 | By Victoria Rees (Drug Target Review) An antibody with high neutralising potency against SARS-CoV-2 that binds to the N terminal domain of the Spike protein has been identified by a team researching COVID-19 therapeutics.
article 3D bioprinting COVID-19 lung models for drug development 19 June 2020 | By Hannah Balfour (Drug Target Review) Keith Murphy, CEO of Viscient Biosciences, discusses the process of developing a 3D bioprinted tissue model and their potential in developing therapeutics for COVID-19 and other diseases.
news Screening reveals nelfinavir and amodiaquine combat COVID-19 in cell cultures 18 June 2020 | By Victoria Rees (Drug Target Review) Researchers who screened 136 broad-spectrum antivirals identified six with the most activity against COVID-19 and an optimum combination of two to fight the virus.
news Decoy nanoparticles show success in cell cultures as COVID-19 therapy 18 June 2020 | By Victoria Rees (Drug Target Review) Researchers have developed 'nanosponges' cloaked in lung cell membranes and macrophage membranes which they found could attract and neutralise COVID-19 in cell cultures.
news New antibody cocktail developed as potential therapy for COVID-19 17 June 2020 | By Victoria Rees (Drug Target Review) Researchers have proposed a cocktail of two antibodies which they say could provide an effective therapy for COVID-19 patients.
news “Potent” antibodies provide protection from COVID-19 in cell cultures, finds study 16 June 2020 | By Victoria Rees (Drug Target Review) Newly discovered antibodies found in the blood of recovered COVID-19 patients could provide robust protection against SARS-CoV-2, say researchers.
news Naphthalene-based PLpro inhibitors show potential as COVID-19 therapeutics 12 June 2020 | By Victoria Rees (Drug Target Review) A group of small molecules called naphthalene-based PLpro inhibitors have been shown to block the activity of a SARS-CoV-2 protein, demonstrating potential as COVID-19 therapeutics.
article What immuno-oncology research can tell us about COVID-19 11 June 2020 | By Dr Jing Watnick (Vigeo Therapeutics) Dr Jing Watnick discusses how lessons learnt from cancer immunotherapy treatments could be applied to the development of COVID-19 therapies.
news Rod-shaped microparticles could improve immune system response to COVID-19 11 June 2020 | By Victoria Rees (Drug Target Review) Researchers have suggested that neutrophils, which contribute to the development of ARDS in COVID-19 patients, could be diverted from the lungs by rod-shaped particles in a new form of treatment.
